據報內地第三輪藥品集中採購將於兩個月內舉行
據《中國證券報》報道,內地由國家醫保局組織的第三輪帶量採購行動將於兩個月內舉行,參與集採的區域為全國32個省(區、市)的公立醫院,藥品品種數量為35個,其中不少屬於高血壓、糖尿病這兩類慢性病的用藥。本輪帶量採購方案將調整部分規則,例如中標的生產廠商最多可達6間。
中標原則方面,仍然採用最低價中標的方式,允許多間企業中標。中標企業的數量為n-1,例如7間投標,6間中標。另外,在報價上採用淘汰制,一旦企業的報價超過最低價的1.8倍,將直接出局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.